Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Minerva Neurosciences Q2 EPS $(1.12) Misses $(0.44) Estimate; Cash, Cash Equivalents, And Restricted Cash Of $$51.9M

Author: Benzinga Newsdesk | August 01, 2023 07:34am
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.44) by 154.55 percent. This is a 31.29 percent increase over losses of $(1.63) per share from the same period last year.

Posted In: NERV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist